Healthcare
RemeGen Co., Ltd.(REGMF)
Live Price
Offline$12.05
+0.00% today
1Y Change
+138.14%
Window
Jun 23, 2025 β Jun 15, 2026
- Market Cap
- $71.56B
- Revenue Growth
- +85.2%
- EPS Growth
- +146.2%
- Dividend Yield
- 0.0%
Coverage: 253 bars Β· Jun 23, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RemeGen Co., Ltd. (REGMF) is a Healthcare stock with a market cap of $71.56B and listed on OTC. The stock last traded around $12.05 and up 138.1% across the available one-year price window (Jun 23, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of +85.2%, EPS growth of +146.2%, a dividend yield of 0.0%. What stands out right now is revenue +85.2%, EPS +146.2%, free cash flow +90.3% with operating margin 28.0% and ROIC 15.5%. Valuation already assumes a fairly strong business story at P/E 56.0 and price/sales 21.2. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines REGMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+85.2% vs +7.6% peer median
Operating Margin
Above sector median
+28.0% vs +19.4% peer median
P/E
Above sector median
56.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +85.2% and EPS at +146.2%, with operating margin around 28.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | β | +0.0% | +0.0% | +10.1% |
2026 Mar 27, 2026 | β | +0.0% | +0.0% | +0.0% |
2025 Aug 22, 2025 | β | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REGMF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
REGMF Max Drawdown
-18.11%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for REGMF and SPY.
Company Overview
RemeGen Co., Ltd.
Other OTC
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, SjΓΆgren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
- Leadership
- Jianmin Fang
- IPO Date
- Jan 21, 2021
- Employees
- 3.0k
- Street Address
- 58 Middle Beijing Road
- Mailing
- Yantai
- Region
- Yantai, CN
- Reporting Currency
- USD
- Investor Line
- 86 53 56357 3672
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 56.0
- EV/EBITDA
- 66.2
- Price/Sales
- 21.2
- Price/Book
- 18.4
Growth
- Revenue
- +85.2%
- EPS
- +146.2%
- Free Cash Flow
- +90.3%
Profitability
- Gross Margin
- 99.1%
- Operating Margin
- 28.0%
- Net Margin
- 38.2%
- ROE
- 42.3%
- ROIC
- 15.5%
Balance Sheet
- Debt/Equity
- 0.53
- Current Ratio
- 1.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.